NCT02536495View on ClinicalTrials.gov

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2018

Conditions
Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma
Interventions
DRUG

Docetaxel

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Selinexor

Given PO

Sponsors

Lead Sponsor

Erin Bertino
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Erin Bertino

OTHER